Isoform-selective histone deacetylase inhibitors
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer. As a result, multiple small molecule HDAC inhibitors are in various phases of clinical trials as anti-cancer drugs. The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes. This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors. The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylases (HDACs) are epigenetic regulators that modulate gene expression by removing acetyl groups from lysine residues on proteins, affecting processes like cell proliferation, differentiation, and development.504,505”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [504]
Citations
Cites
Epigenetic programming by maternal behavior
Weaver, I. C. G., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, J. R., Dymov, S., Szyf, M., & Meaney, M. J. (2004) · Nature Neuroscience · doi:10.1038/nn1276 · Cited by 6,177
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
(2002) · PubMed · Cited by 732
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Research works printed but not linked: 1
- Furumai, 2002, Cancer Res., 62, 4916
Cited by
Items 201–300 of 396
Raimondi, L., Luca, A. D., Giavaresi, G., Barone, A., Tagliaferri, P., Tassone, P., & Amodio, N. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180629153141 · Cited by 19
Molecular docking and ADMET analysis of hydroxamic acids as HDAC2 inhibitors
Alsawalha, M., Bolla, S. R., Kandakatla, N., Srinivasadesikan, V., Veeraraghavan, V. P., & Surapaneni, K. M. (2019) · Bioinformation · doi:10.6026/97320630015380 · Cited by 19
Ganai, S. A. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0673-9 · Cited by 18
Vorinostat-Like Molecules as Structural, Stereochemical, and Pharmacological Tools
Hanessian, S., Auzzas, L., Larsson, A., Zhang, J., Giannini, G., Gallo, G., Ciacci, A., & Cabri, W. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100028g · Cited by 20
Zhang, Y., Feng, J., Liu, C., Fang, H., & Xu, W. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.046 · Cited by 18
Atherogenic Factors and Their Epigenetic Relationships
Fernández, A. Z., Siebel, A. L., & El‐Osta, A. (2010) · International Journal of Vascular Medicine · doi:10.1155/2010/437809 · Cited by 18
Epigenetic induction of melatonin MT 1 receptors by valproate: Neurotherapeutic implications
Bahna, S. G., & Niles, L. P. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.002 · Cited by 17
Fukui, Y., Narita, K., Dan, S., Yamori, T., Ito, A., Yoshida, M., & Katoh, T. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.044 · Cited by 19
Al-Amily, D. H., & Mohammed, M. H. (2019) · Scientia Pharmaceutica · doi:10.3390/scipharm87040028 · Cited by 18
Bieliauskas, A. V., Weerasinghe, S. V. W., Negmeldin, A. T., & Pflum, M. K. H. (2016) · Archiv der Pharmazie · doi:10.1002/ardp.201500472 · Cited by 17
Self-citationZinc-Dependent Histone Deacetylases in Lung Endothelial Pathobiology
Patil, R. S., Maloney, M. E., Lucas, R., Fulton, D. J., Patel, V. S., Bagi, Z. A., Kovács‐Kása, A., Kovács, L., Su, Y., & Verin, A. D. (2024) · Biomolecules · doi:10.3390/biom14020140 · Cited by 17
Predicting the unpredictable: Recent structure–activity studies on peptide-based macrocycles
Wahyudi, H., & McAlpine, S. R. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.04.009 · Cited by 16
Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells
Ononye, S. N., VanHeyst, M. D., Giardina, C. A., Wright, D. L., & Anderson, A. C. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.018 · Cited by 16
Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition
Cianferotti, C., Faltoni, V., Cini, E., Ermini, E., Migliorini, F., Petricci, E., Taddei, M., Salvini, L., Battistuzzi, G., Milazzo, F. M., et al. (2021) · Chemical Communications · doi:10.1039/d0cc06131j · Cited by 19
Epigenetic-based therapies in the preclinical and clinical treatment of Huntington's disease
Valor, L. M. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.04.009 · Cited by 17
Hrzenjak, A., Dieber‐Rotheneder, M., Moinfar, F., Petru, E., & Zatloukal, K. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.013 · Cited by 15
Histone deacetylases and cardiovascular cell lineage commitment
Yang, J., Wang, Q., Wang, W., & Zeng, L.-F. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i5.852 · Cited by 16
From Natural Compounds to Bioactive Molecules through NMR and In Silico Methodologies
Vita, S. D., Terracciano, S., Bruno, I., & Chini, M. G. (2020) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202000469 · Cited by 15
Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1
Gendarme, M., Baumann, J., Ignashkova, T. I., Lindemann, R. K., & Reiling, J. H. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-03-0176 · Cited by 15
Zhang, K., Yao, Y., Tu, Z., Liao, C., Wang, Z., Qiu, Y., Chen, D., Hamilton, D. J., Li, Z., & Jiang, S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0290 · Cited by 14
Human genetics of diabetic retinopathy
Tang, Z.-H., Wang, L., Zeng, F., & Zhang, K. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0172-8 · Cited by 15
A Comparative Study of Target Engagement Assays for HDAC1 Inhibitor Profiling
Asawa, R. R., Zakharov, A. V., Niehoff, T., Ata, C., Jadhav, A., Henderson, M. J., Simeonov, A. M., & Martinez, N. J. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219883625 · Cited by 14
Chemical Tools for Probing Histone Deacetylase (HDAC) Activity
Minoshima, M., & Kikuchi, K. (2015) · Analytical Sciences · doi:10.2116/analsci.31.287 · Cited by 12
Development of New Inhibitors of HDAC1–3 Enzymes Aided by In Silico Design Strategies
Cheshmazar, N., Hemmati, S., Hamzeh‐Mivehroud, M., Sokouti, B., Zessin, M., Schutkowski, M., Sippl, W., Charoudeh, H. N., & Dastmalchi, S. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01557 · Cited by 13
Dai, B., Giardina, C. A., & Rasmussen, T. P. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-305-3_13 · Cited by 13
Jones, J. A., Wei, N., Cui, H., Shi, Y., Fu, G., Rauniyar, N., Shapiro, R., Morodomi, Y., Berenst, N., Dumitru, C. D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112632 · Cited by 20
Zap‐Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat
Troelsen, K. R., Calder, E. D. D., Skwarska, A., Sneddon, D., Hammond, E. M., & Conway, S. J. (2021) · ChemMedChem · doi:10.1002/cmdc.202100403 · Cited by 11
Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies
Patel, P., Shrivastava, S. K., Sharma, P. A., Kurmi, B. D., Shirbhate, E., & Rajak, H. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2192804 · Cited by 12
Hydroxamates of para-aminobenzoic acid as selective inhibitors of HDAC8
Kulandaivelu, U., Chilakamari, L. M., Jadav, S. S., Rao, T. R., Jayaveera, K. N., Boyapati, S., Hauser, A., Senger, J., Marek, M., Romier, C., et al. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.08.005 · Cited by 13
Canzoneri, J. C., Chen, P. C., & Oyelere, A. K. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.028 · Cited by 12
Epigenetic control of microsomal prostaglandin E synthase-1 by HDAC-mediated recruitment of p300
Fork, C., Vasconez, A. E., Janetzko, P., Angioni, C., Schreiber, Y., Ferreirós, N., Geißlinger, G., Leisegang, M. S., Steinhilber, D., & Brandes, R. P. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m072280 · Cited by 12
Rebelo, B. A., Santos, R. B., Ascenso, O. S., Nogueira, A. C., Lousa, D., Abranches, R., & Ventura, M. R. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103452 · Cited by 13
Anticancer Ruthenium Complexes with HDAC Isoform Selectivity
Cross, J. M., Blower, T. R., Kingdon, A. D. H., Pál, R., Picton, D. M., & Walton, J. W. (2020) · Molecules · doi:10.3390/molecules25102383 · Cited by 15
Histone Deacetylase Inhibitors Reduce Cysts by Activating Autophagy in Polycystic Kidney Disease
Sun, L., Hu, C., & Zhang, X. (2019) · Kidney Diseases · doi:10.1159/000499368 · Cited by 12
Sakamoto, K., Hirano, A., Hidaka, R., Suzuki, A. Z., Ueno, T., & Furuta, T. (2022) · Chemical Communications · doi:10.1039/d2cc03552a · Cited by 12
Pham-the, H., & Le-thi-thu, H. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i2.22995 · Cited by 10
Different Groups of HDAC Inhibitors Based on Various Classifications
Ganai, S. A. (2019) · Springer eBooks · doi:10.1007/978-981-13-8019-8_5 · Cited by 11
Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron
Kavianpour, P., Gemmell, M., Kahlert, J. U., & Rendina, L. M. (2020) · ChemBioChem · doi:10.1002/cbic.202000131 · Cited by 11
Pahari, A. K., Mukherjee, J. P., & Chattopadhyay, S. K. (2014) · Tetrahedron · doi:10.1016/j.tet.2014.07.045 · Cited by 11
Vorinostat Corrects Cognitive and Non-Cognitive Symptoms in a Mouse Model of Fragile X Syndrome
Ding, Q., Wu, X., Li, X., & Wang, H. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab081 · Cited by 10
Epigenetics in ADPKD: Understanding Mechanisms and Discovering Treatment
Li, X. (2015) · Codon Publications eBooks · doi:10.15586/codon.pkd.2015.ch12 · Cited by 14
Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
Quambusch, L., Landel, I., Depta, L., Weisner, J., Uhlenbrock, N., Müller, M. P., Glanemann, F., Althoff, K., Siveke, J. T., & Rauh, D. (2019) · Angewandte Chemie · doi:10.1002/ange.201909857 · Cited by 10
Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal
Boateng, A. T., Abaidoo-Myles, A., Bonney, E. Y., & Kyei, G. B. (2022) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0195 · Cited by 14
Forouzesh, F., Ghiaghi, M., & Rahimi, H. (2020) · EXCLI journal · doi:10.17179/excli2020-2010 · Cited by 16
Erwin, N., De, U., Xiao, Y., Wang, L., Maharjan, C. K., Pan, X., Zuo, D., Awasthee, N., Zheng, G., Liao, D., et al. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70211 · Cited by 16
Discovery of selective HDAC6 inhibitors based on a multi-layer virtual screening strategy
Liu, X., Yan, W., Wang, S., Lu, M., Yang, H., Chai, X., Shi, H., Zhang, Y., & Jia, Q. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107036 · Cited by 9
The impact of plant–pathogen studies on medicinal drug discovery
Ottmann, C., van der Hoorn, R. A. L., & Kaiser, M. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15301g · Cited by 9
McCarthy, M. M., & Rissman, E. F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397175-3.00052-1 · Cited by 13
Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker
Cohen, A. L., Neumayer, L. A., Boucher, K. M., Factor, R. E., Shrestha, G., Wade, M. L., Lamb, J. G., Arbogast, K., Piccolo, S., Riegert, J., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00011 · Cited by 9
Omidkhah, N., Eisvand, F., Hadizadeh, F., Zarghi, A., & Ghodsi, R. (2022) · ChemistrySelect · doi:10.1002/slct.202201239 · Cited by 10
Terracciano, S., Chini, M. G., Riccio, R., Bruno, I., & Bifulco, G. (2012) · ChemMedChem · doi:10.1002/cmdc.201100531 · Cited by 9
Ourailidou, M. E., Leus, N. G. J., Krist, K., Lenoci, A., Mai, A., & Dekker, F. J. (2016) · MedChemComm · doi:10.1039/c6md00375c · Cited by 10
Chen, C., Wang, S., Su, Y., Lin, Y. A., & Lin, P. (2017) · Chemistry - An Asian Journal · doi:10.1002/asia.201700339 · Cited by 9
Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors
Tian, Y., Lv, W., Li, X., Wang, C., Wang, D., Wang, P. G., Jin, J., & Shen, J. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.004 · Cited by 9
Zhou, Y., Luo, Q., Gu, L., Tian, X., Zhao, Y., Zhang, Y., & Wang, F. (2025) · Pharmaceuticals · doi:10.3390/ph18040563 · Cited by 13
Synthesis of HC-Toxin via Matteson Homologation and C–H Functionalization
Kohr, M., & Kazmaier, U. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c00914 · Cited by 8
A short enantioselective total synthesis of (R)- and (S)-pipecolic acid
Chavan, S. P., Khairnar, L. B., Chavan, P. N., & Kalbhor, D. B. (2014) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2014.08.001 · Cited by 8
Aboukhatwa, S. M., Hanigan, T. W., Taha, T. Y., Jayaprakash, N., Ranjan, R., El-Bastawissy, E. A., Elkersh, M. A., El-Moselhy, T. F., Frasor, J. M., Mahmud, N., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900114 · Cited by 8
A histone deacetylase-dependent screen in yeast
Weerasinghe, S. V. W., Wambua, M. K., & Pflum, M. K. H. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.045 · Cited by 8
Self-citationMao, N., Xu, Y., Yao, X., Gao, Y., Hui, Z., Che, H., Wang, C., Lu, J., Yu, J., Hu, S., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107973 · Cited by 9
OleD Loki as a Catalyst for Hydroxamate Glycosylation
Hughes, R. R., Shaaban, K. A., Ponomareva, L. V., Horn, J., Zhang, C., Zhan, C., Voss, S. R., Leggas, M. L., & Thorson, J. S. (2019) · ChemBioChem · doi:10.1002/cbic.201900601 · Cited by 8
Butler, M. S. (2009) · Royal Society of Chemistry eBooks · doi:10.1039/9781847559890-00321 · Cited by 7
Effect of Bioactive Nutriments in Health and Disease: The Role of Epigenetic Modifications
Bautista-García, P. B., González‐López, L., Esparza, B. G., & Castillo‐Rosas, C. D. (2017) · InTech eBooks · doi:10.5772/intechopen.68789 · Cited by 7
Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation
Dewaker, V., Srivastava, P. N., Verma, S. K., Srivastava, A. K., & Prabhakar, Y. S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1989037 · Cited by 7
Chakrabarty, S., Jasmine, J., Bhadaliya, C., Sinha, B. N., Mahesh, A., Bai, H., Blond, S. Y., & Jayaprakash, V. (2010) · Archiv der Pharmazie · doi:10.1002/ardp.200900117 · Cited by 7
Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases
Donald, A., Clark, V. L., Patel, S. R., Day, F. A., Rowlands, M., Wibata, J., Stimson, L., Hardcastle, A., Eccles, S. A., McNamara, D., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.016 · Cited by 7
New Applications of Immobilized Metal Ion Affinity Chromatography in Chemical Biology
Codd, R., Gu, J., Ejje, N., & Lifa, T. (2014) · Wiley eBooks · doi:10.1002/9781118682975.ch1 · Cited by 9
Lowe, B. D., & Fletcher, S. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130312 · Cited by 6
PJA2 Suppresses Colorectal Cancer Progression by Controlling HDAC2 Degradation and Stability
Chen, Z., Peng, C., Jin, C., Wang, Y., Wang, T., Yang, P., Peng, W., Sun, Q., Xu, H., Nie, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202401964 · Cited by 6
Zhang, X., Patel, D., Xu, Q., & Veenstra, R. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082288 · Cited by 6
Mao, N., Gao, Y., Dang, X., Duan, J., Hui, Z., Che, H., Xu, Y., Zhang, H., He, X., Garrido, C., et al. (2023) · ChemMedChem · doi:10.1002/cmdc.202200683 · Cited by 6
Total synthesis and biological evaluation of histone deacetylase inhibitor WF-3161
Kohr, M., Papenkordt, N., Jung, M., & Kazmaier, U. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob00641g · Cited by 6
The role of epigenetic changes in the pathology and treatment of inherited retinal diseases
Miller, A. L., James, R. E., Harvey, A. R., Trifunović, D., & Carvalho, L. S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1224078 · Cited by 7
Leonetti, F., Muncipinto, G., Stefanachi, A., Nicolotti, O., Cellamare, S., Catto, M., Pisani, L., Pellegrino, G., & Carotti, A. (2012) · Tetrahedron Letters · doi:10.1016/j.tetlet.2012.05.124 · Cited by 6
Dewaker, V., Srivastava, A. K., Arora, A., & Prabhakar, Y. S. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1780940 · Cited by 7
Bhagat, S. D., Chanchal, A., Gujrati, M., Banerjee, A., Mishra, R. K., & Srivastava, A. (2020) · Biomaterials Science · doi:10.1039/d0bm01417f · Cited by 6
Dewaker, V., & Prabhakar, Y. S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266250924230920042845 · Cited by 5
Bhatia, S., Yan, Y., Ly, M., & Wells, P. G. (2021) · Toxicology Letters · doi:10.1016/j.toxlet.2021.12.010 · Cited by 5
Rosenstock, T. R. (2014) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.886877 · Cited by 6
A cyclodextrin-capped histone deacetylase inhibitor
Amin, J., Puglisi, A., Clarke, J., Milton, J., Wang, M., Paranal, R. M., Bradner, J. E., & Spencer, J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.084 · Cited by 5
Zhou, X., Alimu, A., Zhao, J., Xu, X., Li, X., He, L., & Lin, Z. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01512-2 · Cited by 4
Total Synthesis of the Depsipeptide FR901375 and Preliminary Evaluation of Its Biological Activity
Narita, K., Katoh, Y., Ojima, K.-I., Dan, S., Yamori, T., Ito, A., Yoshida, M., & Katoh, T. (2016) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201601023 · Cited by 4
Wang, C., Lei, L., Yang, X., Li, Y., Zhang, J., Xu, Y., & Si, S. (2024) · Pharmaceuticals · doi:10.3390/ph17040425 · Cited by 6
Kollár, J., & Frecer, V. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.08.008 · Cited by 4
Erwin, N., De, U., Xiao, Y., Wang, L., Maharjan, C. K., Pan, X., Awasthee, N., Zheng, G., Liao, D., Zhang, W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.25.609564 · Cited by 4
Tsutsumi, H., Nakano, K., & Mihara, H. (2015) · Molecular BioSystems · doi:10.1039/c5mb00316d · Cited by 3
Hua, F., Sun, J., Guo, F., Yin, S., Zhang, Q.-L., Zhang, W., & Liang, W. (2014) · PubMed · Cited by 3
Elmezayen, A. D., Al-Obaidi, A., & Yelekçi, K. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.107937 · Cited by 4
Nucleus translocation of tRNA synthetase mediates late integrated stress responsePreprint
Wei, N., Cui, H., Shi, Y., Fu, G.-S., Rauniyar, N., Yates, J., & Yang, X.-L. (2020) · bioRxiv · doi:10.1101/2020.06.07.138792 · Cited by 3
Thomas, E. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805420-8.00007-x · Cited by 2
Prestegui-Martel, B., Chávez-Blanco, A. D., Domínguez-Gómez, G., González, A. D., Gaona-Aguas, P., Flores-Mejía, R., Somilleda-Ventura, S. A., Rodríguez‐Cortés, O., Morales‐Bárcenas, R., Muñoz, A. M., et al. (2024) · Molecules · doi:10.3390/molecules29153509 · Cited by 2
Zhang, X., Lv, P., Li, D., Zhang, W.-M., & Zhu, H. (2015) · MedChemComm · doi:10.1039/c5md00247h · Cited by 2
Clinical Applications of Histone Deacetylase Inhibitors
Pacaud, R., García, J., Thomas, S., & Münster, P. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91909-8.00002-5 · Cited by 2
Histone Deacetylase Inhibitors: A Novel Therapeutic Approach for Cognitive Disorders
Labrie, V. (2011) · Springer eBooks · doi:10.1007/978-3-642-17426-1_12 · Cited by 2
Ganai, S. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-8179-3_8 · Cited by 2
Insight in Quinazoline-based HDAC Inhibitors as Anti-cancer Agents
Martino, E., Thakur, S., Kumar, A., Yadav, A. K., Boschi, D., Kumar, D., & Lolli, M. L. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575303614240527093106 · Cited by 2
Shukla, D., Matore, B. W., Murmu, A., Gawande, P., Roy, P. P., & Singh, J. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2605010 · Cited by 2
Targeted HDAC8 inhibition with non-hydroxamate [1,2,4]triazolo[4,3-a] quinoline compounds
Bandaru, N. V. M. R., Fathima, A., Sengar, S., Schweipert, M., Chaitanya, K. S., Mohammed, M.-U.-R., Gore, S. T., Trinath, J., Sharma, V., Abbineni, C., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-38490-y · Cited by 1
El-hameed, A. I. A., Salem, I. M., Allam, R. M., Arafat, M. M., Aziz, H. A., Awan, Z. A., Ibrahim, T. S., Alshazly, O., Beshr, E. A. M., Bräse, S., et al. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2711875 · Cited by 1
Stilger, K. L. (2014) · IUScholarWorks (Indiana University) · doi:10.7912/c2/303 · Cited by 1
Metadata
- Authors
- Bieliauskas, A. V., & Pflum, M. K. H.
- Affiliations
- Wayne State University (US)
- Corresponding author
- Pflum, Mary Kay H.
- ORCID
- Pflum, Mary Kay H.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2008
- Volume
- 37
- Issue
- 7
- Pages
- 1402
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- PMC
- PMC2593472
- OpenAlex
- W2124258829
- Cited by
- 350
- References
- 59
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 15 · 2023: 16 · 2022: 10 · 2021: 12 · 2020: 21 · 2019: 20 · 2018: 19 · 2017: 16 · 2016: 21 · 2015: 21 · 2014: 27 · 2013: 22 · 2012: 22
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (GM 067657, R01GM067657)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- histone deacetylase inhibitors, HDAC isoforms, isoform selectivity, cancer therapy, small molecule inhibitors, transcriptional regulation
- MeSH terms
- Vorinostat, Antineoplastic Agents, Binding Sites, Enzyme Inhibitors, Histone Deacetylases, Humans, Hydroxamic Acids, Tumor Cells, Cultured, Drug Design, Protein Isoforms, Cell Proliferation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.